Quelques réflexions sur un espace composé

L’idée d’entité sonore englobe les aspects physiques du phénomène sonore et ceux perceptifs dans un réseau d’opérations manipulables au niveau de la composition musicale (sonore). L’entité sonore ne pourra, par ses particularités, être objectivement définie que par l’ensemble d’éléments disparates qui la constituent lesquels ne semblent pas a priori cohésifs. Cependant, la technologie actuelle autorise l’accès non seulement à l’extériorité mais également à l’intériorité du son, rendant possible l’intégration logique de toutes ses hétérogénéités. Fondée sur des opérations, des articulations, mais également sur des perceptions, l’entité sonore inclut l’acte même de composition : des schémas opératoires, des interactions et des articulations en font partie. Ainsi conçue dans le contexte musical, elle est un élément qui interagit, qui agit, qui réagit et qui accepte des transformations dans le contexte compositionnel où elle est utilisée ou construite. Le son ainsi composé, considéré comme un ensemble de perceptions, d’éléments manipulables, d’opérations possibles à tous les niveaux temporels, est une présence porteuse d’espace.

La forme sonore des ancêtres. Phonogrammes et séquences-mémoires sonores chez les Bijagó (Guinée-Bissau)

Cahiers d'ethnomusicologie, V.22, pp. 223-237

La notion d’Espace dans la création musicale : idées, concepts et attributions Une réflexion à propos d’espaces intentionnellement perçus ou composés de l’entité sonore

Notre étude présente une réflexion à propos de espaces musicaux composables. Cette réflexion inclue l’usage intentionnel des qualités sonores perçues dans la construction de sons et donc dans la composition musicale. Nos recherches se trouvent à l’intersection entre le son, comme phénomène physique qui se propage dans un espace, les sensations spatiales qui peuvent être engendrées par la perception auditive de ses certaines caractéristiques, et la pratique de la composition musicale d’espaces de sons dans les œuvres. Nous développons l’idée d’une entité sonore composable dès sa microstructure. Nous la concevons par analogie avec les objets du monde visible et palpable. Nous utilisons les idées de volume, forme et matière ainsi que celles de position et de mouvement des objets matériels, comme métaphore pour concevoir des entités sonores complexes et des espaces musicaux composés dans lesquels elles seront intégrées. Cette entité sonore constituée d’un ensemble d’éléments disparates, permet le développement de réseaux opératoires manipulables dans, la pratique, par les compositeurs.

Pregnancy outcome following maternal exposure to Mirtazapine: Preliminary results of a collaborative ENTIS study.

Introduction: Mirtazapine is a noradrenergic and serotonergic antidepressant mainly acting through blockade of presynaptic alpha-2 receptors. Published data on pregnancy outcome after exposure to mirtazapine are scarce. This study addresses the risk associated with exposure to mirtazapine during pregnancy. Patients (or Materials) and Methods: Multicenter (n = 11), observational prospective cohort study comparing pregnancy outcomes after exposure to mirtazapine with 2 matched control groups: exposure to any selective serotonin reuptake inhibitor (SSRI) as a diseasematched control group, and general controls with no exposure to medication known to be teratogenic or to any antidepressant. Data were collected by members of the European Network of Teratology Information Services (ENTIS) during individual risk counseling between 1995 and 2011. Standardized procedures for data collection were used in each center. Results: A total of 357 pregnant women exposed to mirtazapine at any time during pregnancy were included in the study and compared with 357 pregnancies from each control group. The rate of major birth defects between the mirtazapine and the SSRI group did not differ significantly (4.5% vs 4.2%; unadjusted odds ratio, 1.1; 95% confidence interval, 0.5-2.3, P = 0.9). A trend toward a higher rate of birth defects in the mirtazapine group compared with general controls did not reach statistical significance (4.2% vs 1.9%; OR, 2.4; 95% CI, 0.9-6.3; P = 0.08). The crude rate of spontaneous abortions did not differ significantly between the mirtazapine, the SSRI, and the general control groups (9.5% vs 10.4% vs 8.4%; P = 0.67), neither did the rate of deliveries resulting in live births (79.6% vs 84.3% in both control groups; P = 0.15). However, a higher rate of elective pregnancy-termination was observed in the mirtazapine group compared with SSRI and general controls (7.8% vs 3.4% vs 5.6%; P = 0.03). Premature birth (< 37 weeks) (10.6% vs 10.1% vs 7.5%; P = 0.38), gestational age at birth (median, 39 weeks; interquartile range (IQR), 38-40 in all groups; P = 0.29), and birth weight (median, 3320 g; IQR, 2979-3636 vs 3230 g; IQR, 2910-3629 vs 3338 g; IQR, 2967-3650; P = 0.34) did not differ significantly between the groups. Conclusion: This study did not observe a statistically significant difference in the rate of major birth defects between mirtazapine, SSRI-exposed, and nonexposed pregnancies. A slightly higher rate of birth defects was, however, observed in the mirtazapine and SSRI groups compared with the low rate of birth defects in our general controls. Overall, the pregnancy outcome after mirtazapine exposure in this study is very similar to that of the SSRI-exposed control group.

Preliminary results of venlafaxine exposure in pregnancy, a multicenter prospective cohort ENTIS study

Introduction: Venlafaxine (Efexor®) is a serotonin and noradrenaline reuptake inhibitor (SNRI) used for the treatment of depression and anxiety disorders. The limited data on the use of venlafaxine in human pregnancy do not indicate an increased risk of congenital malformations. The main purpose of the study is to assess the rate of major malformations after first trimester exposure to venlafaxine. Methods: This multicenter, prospective cohort study was performed using data from nine centers who are member of the European Network of Teratology Information Services (ENTIS). Data on pregnancy and pregnancy outcome of women who used venlafaxine in pregnancy were collected during individual risk counseling. Standardized procedures for data collection and followup were used by each center. Results: Follow up data were collected on 744 pregnancies of womenwhoused venlafaxine during gestation. In 583 (78.4%) cases the exposure had occurred at least in the first trimester. In total, there were 600 live births (5 twins), 85 spontaneous abortions, 57 elective terminations of pregnancy, 5 fetal deaths, and 2 ectopic pregnancies. The overall rate of major malformations after first trimester exposure and excluding chromosomal and genetic disorders was 3.2% (16/500) in all pregnancies ending in delivery, pregnancy terminations or fetal deaths with fetal-pathological examination. Among live births the malformation rate was 2.7% (13/490). We observed no increased risk for organ specific malformations. Conclusions: The present study indicates that venlafaxine is not a major human teratogen.

De summi entis necessitate

Painovuosi nimekkeestä.

De affectionibus entis in genere

Invokaatio: En to tou Theou upsitou onomati.

De conceptibus entis secundariis

Invokaatio: I.N.J.

De entis natura ejusque conceptu

Invokaatio: Jehovah adsistente.